Adding to Tarceva in a Broad NSCLC Population: Weighing Benefits with Risks episode artwork

EPISODE · Jul 5, 2015 · 2 MIN

Adding to Tarceva in a Broad NSCLC Population: Weighing Benefits with Risks

from GRACEcast · host cancerGRACE Meetings

A trial comparing Tarceva (erlotinib) to Cometriq (cabozantinib) showed modest benefit for EGFR wild type patients, but the challenging side effect profile should lead us to question if we can identify only patients most likely to benefit from Cometriq.

Episode metadata supplied by the publisher feed · Published Jul 5, 2015

Embed this episode

NOW PLAYING

Adding to Tarceva in a Broad NSCLC Population: Weighing Benefits with Risks

0:00 2:58

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of GRACEcast?

This episode is 2 minutes long.

When was this GRACEcast episode published?

This episode was published on July 5, 2015.

Can I download this GRACEcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!